EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanism of nimodipine in treating neurodegenerative diseases: in silico target identification and molecular dynamic simulation

Mechanismus von Nimodipin bei der Behandlung neurodegenerativer Erkrankungen: in silico Target-Identifikation und molekulardynamische Simulation

Shuang Zheng, Yin Wang, Shuainan Tang, Yuntao Guo, Duan Ma, Xin Jiang

Frontiers in Pharmacology · 13.03.2025 · 16

DOI: 10.3389/fphar.2025.1549953 ↗

Auf einen Blick

Die Arbeit untersuchte mögliche Targets und Mechanismen von Nimodipin bei neurodegenerativen Erkrankungen. Im Fokus stand MAOA als potenzielles Zielprotein mit stabiler Bindung in der Simulation.

Fragestellung

Welche Targets und Mechanismen könnten die Wirkung von Nimodipin bei neurodegenerativen Erkrankungen erklären?

Methode

In-silico-Analyse: Target-Vorhersage mit SwissTargetPrediction, CTD, GeneCards und DrugBank; PPI-Netzwerk mit STRING; GO-/KEGG-Anreicherung mit ClusterProfiler; Docking mit AutoDock Vina; Simulation mit GROMACS.

Ergebnisse

Es wurden 33 überlappende Targets identifiziert; das PPI-Netzwerk umfasste 28 Knoten und 69 Kanten. MAOA zeigte die höchste Bindungsenergie von −7,343 kcal/mol und eine stabile 100-ns-Simulation.

Einschränkungen

In-silico-Studie ohne klinische Daten oder experimentelle Prüfung im Patientenmaterial.

Schlussfolgerung der Autor:innen

Nimodipin bindet an die innere Tasche von MAOA und zeigt potenzielle inhibitorische Effekte. Die Autor:innen vermuten einen therapeutischen Effekt bei NDDs durch MAOA-Hemmung und Modulation von oxidativem Stress im Gehirn.

Kernaussagen

  • 33 überlappende Drug-Disease-Targets wurden identifiziert
  • MAOA zeigte die höchste Bindungsenergie von −7,343 kcal/mol
  • 100-ns-Simulation sprach für eine stabile MAOA-Nimodipin-Bindung

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 13.03.2025. Verfasst von Shuang Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Nimodipine has shown neuroprotective effects in several studies; however, the specific targets and mechanisms remain unclear. This study aims to explore the potential targets and mechanisms of nimodipine in the treatment of neurodegenerative diseases (NDDs), providing a theoretical foundation for repurposing nimodipine for NDDs.

Methods

Drug-related targets were predicted using SwissTargetPrediction and integrated with results from CTD, GeneCards, and DrugBank. These targets were then cross-referenced with disease-related targets retrieved from CTD to identify overlapping targets. The intersecting targets were imported into STRING to construct a protein-protein interaction (PPI) network. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using the R package ClusterProfiler. Molecular docking was carried out using AutoDock Vina, and the ligand-receptor complexes with the highest binding affinities were further simulated using GROMACS to assess the dynamic structural stability and interactions between the ligand and receptor in the dynamic system.

Results

A total of 33 intersecting drug-disease targets were identified. After constructing the PPI network and removing isolated targets, the network contained 28 nodes and 69 edges. Network degree analysis combined with enrichment analysis highlighted 12 key targets: CASP3, TNF, BAX, BCL2, IL1B, GSK3B, IL1A, MAOB, MAOA, BDNF, APP, and GFAP. Molecular docking analysis revealed binding energies greater than −6 kcal/mol for MAOA, GSK3B, MAOB, CASP3, BCL2, IL1B and APP. MAOA, with the highest binding energy of −7.343 kcal/mol, demonstrated a stable structure in a 100ns dynamic simulation with nimodipine, exhibiting an average dynamic binding energy of −52.39 ± 3.05 kcal/mol. The dynamic cross-correlation matrix (DCCM) of nimodipine resembled that of harmine, reducing the interactions between protein residues compared to the apo state (regardless of positive or negative correlations). Furthermore, nimodipine induced new negative correlations in residues 100-200 and 300-400.

Conclusion

Nimodipine binds to the internal pocket of MAOA and shows potential inhibitory effects. Given its brain-enrichment characteristics and proven neuroprotective effects, it is hypothesized that nimodipine may exert therapeutic effects on NDDs by inhibiting MAOA activity and modulating cerebral oxidative stress. Thus, MAOA emerges as a promising new target for nimodipine in the treatment of NDDs.

Schlagwörter

Stichwörter der Autor:innen

calcium channel blockermolecular dockingmolecular dynamics simulationnetwork analysisneurodegenerative diseasenimodipine

Autor:innen und Institutionen

  • School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.
  • Precision Genes Technology, INC., Nantong, China.
  • Yangtze Delta Drug Advanced Research Institute, Nantong, China.

Zitieren

APA

Zheng, S., Wang, Y., Tang, S., Guo, Y., Ma, D., & Jiang, X. (2025). Mechanism of nimodipine in treating neurodegenerative diseases: in silico target identification and molecular dynamic simulation. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1549953

Vancouver

Zheng S, Wang Y, Tang S, Guo Y, Ma D, Jiang X. Mechanism of nimodipine in treating neurodegenerative diseases: in silico target identification and molecular dynamic simulation. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1549953

BibTeX
@article{Zheng2025,
  author = {Zheng, Shuang and Wang, Yin and Tang, Shuainan and Guo, Yuntao and Ma, Duan and Jiang, Xin},
  title = {Mechanism of nimodipine in treating neurodegenerative diseases: in silico target identification and molecular dynamic simulation},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1549953}
}
Kostenlos starten →